UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the Securities Exchange Act of 1934
March 5, 2014
Date
of Report (Date of earliest event reported)
AGENUS INC.
(Exact
name of registrant as specified in its charter)
|
DELAWARE |
000-29089 |
06-1562417 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
3 Forbes Road Lexington, MA |
02421 |
|
(Address of principal executive offices) |
(Zip Code) |
781-674-4400
(Registrant’s
telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (see General Instruction A.2. below):
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 2.02 |
Results of Operations and Financial Condition |
|
On March 5, 2014, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2013. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K. |
|
Item 8.01 |
Other Events |
|
Ludwig Cancer Research and Agenus Inc. today announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development. These product candidates—two GITR agonists and a CTLA-4 antagonist—target cell-surface checkpoint proteins that control immune responses. The full text of the press release issued in connection with the announcement is being filed as Exhibit 99.2 to this current report on Form 8-K. |
|
Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits
The following exhibit is furnished herewith:
99.1 Fourth Quarter and Full Year 2013 Press Release dated March 5, 2014
99.2 Checkpoint Modulator Press Release dated March 5, 2014
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AGENUS INC. |
|||
|
|
|||
|
Date: March 5, 2014 |
By: |
/s/ Garo H. Armen |
|
|
Garo H. Armen |
|||
|
Chief Executive Officer |
|||
EXHIBIT INDEX
|
Exhibit No. |
Description of Exhibit |
|
|
99.1 |
Fourth Quarter and Full Year 2013 Press Release dated March 5, 2014 |
|
|
99.2 |
Checkpoint Modulator Press Release dated March 5, 2014 |